FDA's Crawford Open To Discussing Independent Drug Safety Office
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting Commissioner Crawford tells members of the Senate Health Committee during his confirmation hearing that he is willing to talk about a more independent safety review office. However, the commissioner nominee also says the Office of Drug Safety already is "operating independently."
You may also be interested in...
Drug Safety Legislation To Be Introduced April 27
Sens. Grassley and Dodd are proposing the creation of a “Center for Post-market Drug Evaluation & Research” that would be independent from FDA’s existing drug safety infrastructure. Proposals for an independent drug safety office have elicited mixed reactions from the agency.
Drug Safety Legislation To Be Introduced April 27
Sens. Grassley and Dodd are proposing the creation of a “Center for Post-market Drug Evaluation & Research” that would be independent from FDA’s existing drug safety infrastructure. Proposals for an independent drug safety office have elicited mixed reactions from the agency.
Office Of New Drugs' Oversight Creates Advisory Committee Bias – FDA’s Graham
OND’s role in appointing advisory committee members and deciding what issues receive attention leads to a “pro-drug bias and regulatory conflicts of interest,” Office of Drug Safety’s Graham says. FDA “whistleblower” also criticizes disclosure policies for advisory committee members.